secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001178913-25-003851
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio reports Q3 net loss $3.2M; FDA agrees BMD endpoint for EB613 Phase 3
-------------------------------------------------------------------------------

- Net loss $3.2M ($0.07/share) vs $3.0M ($0.08/share) in Q3 2024; cash $16.6M through mid-Q3 2026.
- FDA agreed BMD as primary endpoint for single Phase 3 trial of EB613 (oral PTH) for osteoporosis; supports NDA.
- EB613 Phase 2 data showed significant BMD gains in younger postmenopausal women, presented at NAMS and ASBMR.
- Next-gen EB613 Phase 1 trial on track for late 2025; GLP-2 and OXM programs with OPKO advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/0001178913-25-003851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/zk2534017.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer